READING, UNITED KINGDOM — Convatec Group Plc ("Convatec”), a leading global medical products and technologies company, welcomes the UK Government’s support for the wound care industry as part of its Life Sciences Sector Deal, and is pleased to set out its commitment to supporting the Government on the objectives it outlined.
Through the Sector Deal, Convatec has been working with the Association of British HealthTech Industries, Health Care Providers and UK Academia, as part of a broader consortium across the healthcare sector, to identify ways to improve patient outcomes and maximise financial efficiency in wound care diagnosis and treatment. This includes the use of new digital clinical decision support tools to support health professionals and patients, helping to reduce variation in treatment and to ensure timely and appropriate care.
Convatec’s contribution will be part of an investment of £10m over three years in UK based wound R&D and academia. Global Research & Development is focused in our facility in Deeside, Wales, and we will partner with NHS Health Providers and UK universities to pilot improvements in patient care. Going forward, the focus of Convatec’s investment will be in enhancing wound provision by supporting improved diagnostics and assessment, developing validated clinical pathways, ensuring greater consistency of care and providing accurate and timely data to help reduce overall management costs while improving clinical outcomes.
Una Adderley, National Wound Care Strategy Programme Director, AHSN Network, said:
“We are delighted that the Life Sciences Sector Deal 2 has included wound care as a focus. Industry and innovation are important in the emerging National Wound Care Strategy Programme and we welcome this opportunity for closer collaborative working to improve care for patients with wounds.”
Simon Whitfield, Vice President & UK General Manager, Convatec, added:
“We are proud to be contributing to the Wound Care Sector Deal, which brings key stakeholders across the NHS, government and industry together to reduce variation in wound assessments and deliver better outcomes for patients and healthcare professionals. Our investment demonstrates Convatec’s support for the deal and illustrates its commitment to improving outcomes and value for patients across the UK.”
Bobby Leach, VP Group Corporate Affairs, Convatec +44 (0)7776 662 787
Alastair Elwen, Finsbury +44 (0)207 251 3801
Analysts and Investors
John Crosse, VP Investor Relations, Convatec +44 (0)7500 141 435
Kirsty Law, Director Investor Relations, Convatec +44 (0)7470 909 582
Convatec is a global medical products and technologies company focused on therapies for the management of chronic conditions, with leading market positions in advanced wound care, ostomy care, continence and critical care, and infusion devices. Convatec’s products provide a range of clinical and economic benefits including infection prevention, protection of at-risk skin, improved patient outcomes and reduced total cost of care. The Company is listed on the London Stock Exchange (stock symbol: CTEC) and is included in the FTSE4Good ethical index.
Download PRESS RELEASEPDF
Q1 Trading Update for the three months ended 31 March 2018Read more
Convatec announces changes within its U.S. Home Distribution GroupRead more
Convatec announces 2018 Interim ResultsRead more
03 July 2018 - Board ChangesRead more
Convatec Receives U.S. FDA 510(k) Clearance for Avelle™ Negative Pressure Wound Therapy SystemRead more
Trading update for the three months ended 30 September 2018 and change in FY 2018 guidanceRead more
Retirement of Chief Executive Officer and appointment of Rick Anderson as Chief Executive Officer (Interim)Read more
US FDA 510(k) clearance for AQUACEL™ Ag AdvantageRead more